TW467746B - Combination vaccines comprising aluminium phosphate adsorbed HIB conjugates and the method for the production thereof - Google Patents
Combination vaccines comprising aluminium phosphate adsorbed HIB conjugates and the method for the production thereof Download PDFInfo
- Publication number
- TW467746B TW467746B TW085107646A TW85107646A TW467746B TW 467746 B TW467746 B TW 467746B TW 085107646 A TW085107646 A TW 085107646A TW 85107646 A TW85107646 A TW 85107646A TW 467746 B TW467746 B TW 467746B
- Authority
- TW
- Taiwan
- Prior art keywords
- vaccine
- adsorbed
- conjugate
- patent application
- polysaccharide
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 96
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 229910000147 aluminium phosphate Inorganic materials 0.000 title claims abstract description 7
- 229940001007 aluminium phosphate Drugs 0.000 title claims abstract 5
- 238000000034 method Methods 0.000 title claims description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 238000009472 formulation Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract description 5
- 229940031348 multivalent vaccine Drugs 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims abstract 4
- 229920001282 polysaccharide Polymers 0.000 claims description 50
- 239000005017 polysaccharide Substances 0.000 claims description 50
- 150000004676 glycans Chemical class 0.000 claims description 49
- 108010078791 Carrier Proteins Proteins 0.000 claims description 24
- 102000014914 Carrier Proteins Human genes 0.000 claims description 24
- 206010013023 diphtheria Diseases 0.000 claims description 21
- 241000606790 Haemophilus Species 0.000 claims description 18
- 206010043376 Tetanus Diseases 0.000 claims description 16
- 238000011049 filling Methods 0.000 claims description 16
- 201000005702 Pertussis Diseases 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 229960000814 tetanus toxoid Drugs 0.000 claims description 12
- 230000002079 cooperative effect Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 241000709721 Hepatovirus A Species 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000001994 activation Methods 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 108010060123 Conjugate Vaccines Proteins 0.000 claims description 5
- -1 H1B polysaccharide Chemical class 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 229940031670 conjugate vaccine Drugs 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 235000015170 shellfish Nutrition 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 101710116435 Outer membrane protein Proteins 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 229960000074 biopharmaceutical Drugs 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 238000002523 gelfiltration Methods 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- 229940001442 combination vaccine Drugs 0.000 claims description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- MEPLNBPJJKOWLV-UHFFFAOYSA-N hexanedioic acid;hydrazine Chemical compound NN.OC(=O)CCCCC(O)=O MEPLNBPJJKOWLV-UHFFFAOYSA-N 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 238000002255 vaccination Methods 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 229940124884 Engerix-B Drugs 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 241000282320 Panthera leo Species 0.000 claims description 2
- 229940124909 PedvaxHIB Drugs 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 239000012506 Sephacryl® Substances 0.000 claims description 2
- 239000008476 aike Substances 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000002309 gasification Methods 0.000 claims description 2
- 210000000003 hoof Anatomy 0.000 claims description 2
- 230000002480 immunoprotective effect Effects 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000012263 liquid product Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 238000010172 mouse model Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims 3
- 206010011224 Cough Diseases 0.000 claims 2
- 241000968335 Cystococcus Species 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 210000002418 meninge Anatomy 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 238000012937 correction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 4
- 208000000474 Poliomyelitis Diseases 0.000 description 3
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 229960002520 hepatitis vaccine Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 229940124914 Havrix Drugs 0.000 description 1
- 229940124915 Infanrix Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 239000004643 cyanate ester Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229960005097 diphtheria vaccines Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- CLFDZWJTRTXHNV-UHFFFAOYSA-N lepidamine Natural products CC1CC(=O)C(=C2C(=O)C(=O)C3C(C3(C)C)C12C)N CLFDZWJTRTXHNV-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
4 67 74 6 第85107646號專利申請案 中文説明書修正頁(87年9月) Λ' ir ^ η2- 經濟部中夬標準局員工消費合作社印製 五、發明説明(1 ) 本發明有關新穎疫苗配方,其包括連接於載體蛋白質之 共軛多醣抗原。本發明特別是有關於預防B型感冒嗜血桿 菌(Hib)感染之疫苗配方,且其抗原吸附在磷酸鋁上。本 發明亦有關於多價疫苗,此類疫苗可以同時改善或治療多 種疾病。本發明亦有關於此類疫苗之生產及其作爲藥物之 用途 應用多醣類作爲疫苗是已知的技藝。例如有預防B型感冒 嗜血桿菌(Hib)感染之疫苗是以與載體蛋白質共軛之被膜 多醣(PRP)爲基礎。此多醣爲由核糖,核糖醇及磷酸而成之 聚合物。這類疫苗通常是單純的配方(不含佐劑)。然而有 一種製劑 (Merck生產之Pedvax Hib)是用含有氫氧化銘之 稀釋液去重组經冷凍乾燥之共軛物。通常載體蛋白質是白 喉或破傷風類毒素或是腦膜炎奈瑟氏球菌(N. menigitidis) 之外膜蛋白質。如此類共軛疫苗抗原之例子揭示如US 4 365 170,US 4 673 574,EP 208 375,EP 477 508及 EP 161 188 ° 一般係欲將此類共軏疫苗與其他的抗原或疫苗同時投藥 ,這可能需作多次注射。多次注射的問題在於投藥的步驟 較複雜及較大的總注射量。當疫苗是用於婴兒時這種問題 更加嚴重。 因此一般均建議生產综合疫苗。其中最熟知的综合疫苗 可以同時抗白喉、破傷風和百日咳感染。此疫苗包含一完 整細胞或非細胞的百日咳成份,通常由2到3個抗原-(去毒 的PT,FHA且常爲但並非只爲69kDa),雖然在某些情況下 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公漦) (請先閱讀背面之注意事項再填寫本頁) 裝. 訂 467746 經濟部中央標率局員工消費合作社印製 A 7 B7五、發明説明(2 ) ,其他的百日咳抗原及白喉類毒素和破傷風毒素亦可存在 。此類之疫苗通常稱爲DTPw或DTPa。其他想要加入综合 疫苗的是如預防B型肝炎或小兒麻痺的抗原。 將多醣共軛疫苗加入如此之综合劑中是所欲的。但是我 們發現單純地將各部分混合會降低對多醣部分所產生抗體 效價。 本案發明人發現此一降低現象可以藉共軛抗原先吸附於 .磷酸鋁而抑制。相反地,如果j支原._吸附於氫氧化鋁,則對 多醣部分所產生之抗體效度完全被降低。 因此本發明提供一種疫苗組成物,其包、會多醣共軛抗原 吸附於磷酸鋁?較佳之抗原是用Hib之被膜多醣(PRP)與載 體蛋白質結合。較佳之載體蛋白質可用白喉或破傷風類毒 素,白喉之Crm197蛋白質或由如腦膜炎奈瑟氏球菌(N. menigitidis)之細菌外膜取得之蛋白質。 、多醣共軛备可用已知偶聯技術中任一種來製備。例如多 醣可以硫醚連接完成偶聯。此種共軛方法 '需以1-.氰基-4-二 甲胺基-吡錠四氟硼酸鹽(CDAP.)來活化多醣以形成氰酸酯 。活化後之多醣可經由間隔基直接與載體蛋白質之胺基偶 —聯。較佳地是氰酸酯與己烷二胺偶聯,而經胺基衍生之多 醣利用異屬融合化學形成硫醚連接而與載體蛋白質共軛。 此類共軛物曾述於PCT已公開申請案WO93/15760,統一服 務大學。 共軛物亦可由直接還原胺化法來製備,揭示如US 4365170(Jeimings)及 US 4673574(Anderson)。其他方法如 I I - · I 1- - - . I 1- - .-_ an^i ml - - n^— ^_ {#先閱讀背面之注意事項再填寫本頁〕 -5- 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X297公釐) 467746 A7 經濟部中央標準局負工消費合作杜印製 ___B7五、發明説明(3 ) EP-0-161-188,EP-208375及EP-0-477508 ° 其他方法在於將以溴化氰活化並經己二酸醯肼(ADH)衍 生之寿醣藉碳二醯亞胺聚合作用與載體蛋白質偶聯。如此 之共耗曾述於Chu C. et al Infec Immunity, 1983/245..256。 在本發明較佳具體實例中PRP多醣與載體蛋白質之比例 由通常的1 : 3降到1 : 0,3至1 : 2。如此低比例的共軛物是 有益的,因爲即使在無佐劑狀況下也無干擾的問題。 本發明較佳具體實例之配方最宜包含至少一種其他的抗 原以便對抗一或多種下列疾病:A型肝炎病毒(HAV),白喉 ,破傷風,百日咳,B型肝炎及小兒麻痒。 在本發明範圍内之特殊综合疫苗包括DTPa(白喉•破傷風-無細胞百日咳)-Hib综合疫苗製劑,Hib-B型肝炎疫苗製劑 ,DTPa-Hib-B型肝炎疫苗製劑及IPV(去活性小兒麻痒疫苗 )-DTPa-Hib-B型肝炎疫苗製劑。 上述諸综合亦可選擇性地包含抗A型肝炎之成份。 適合用於疫苗之各成份均已商業化,詳情可由世界衛生 組織取得。例如IPV成份即可能是沙克去活性小兒麻痒疫苗 。白喉,破傷風與百日咳疫苗可能是無細胞產品,像 Infanrix DTPa(SmithKline Beechara Biologicals)。可以抗 A 型肝炎的成份最宜採用稱爲”1^乂1^"(311^11幻丨1^666(:1^111 Biologicals)之產品,他是種藉殺死病毒而減弱毒性的疫苗 ,源自HM-175品系的HAV[參看·Α型肝炎之去活性候選疫苗· F: E. Andre, A. Hepburn及 E. D’Hondt,Prog Med. Virol. Vol 37,pages 72-95(1990)及Havrix產品解説手册 _,由 SmithKline -6- 本紙浪A度適用中國國家標準(CNS ) A4规格(2i0X297公釐) (請先閲讀背面之注意事項再填寫本頁) •装· -訂
I β 經濟部中央標準局貝工消費合作社印繁 4 ! ί 好'' ^ 7- ^!·: ; w— —... .
74 6 第85 1 〇7646號專利申請案 中文說明書修正頁(87年9月) 五、發明説明(4 )
Beecham BioI〇gicais(i991)出版]。B 型肝炎成份包括 ”s,,枋 原如 ’’Engerix-B"中者= 依本發明所製之B型感冒嗜血桿菌或综合疫苗之極有利 處是它們亦是小兒疫苗3 疫苗之製備揭示於疫苗設計·次單元與佐劑之取向,Ed Powell and Newman; Pellum Press 3 包入脂質體係如 Fullerton,美國專利4,235,877中所描述》蛋白質與大分子 之共梃係如Likhite美國專利4,372,945及Armor等人之美國專 利4,474, 757中所描述。 存在於各個疫苗中共扼抗原之量取決於該量可誘導免疫 保護反應而又無顯著的副作用=此量與用那一個特定的免 疫原有關。通常希望每一劑含1 · 1000微克的免疫原,較佳 是含2-100微克,最佳是含4-40微克。每一特定疫苗之最佳 量可藉標準研究來確定,包括觀察抗體效價及個體之其他 反應。經初次注射疫苗後,個體可能仍需在四個星期間隔 給予一或兩次的補助注射。 本發明更進一步提供一種生產疫苗之方法,包含將共軛 抗原吸附於磷酸鋁3吸附最好是在p Η 5至6間進行,較佳 爲約5,4。在具體實例中,疫苗經多於2 4小時之靜置後冷 凍乾燥。本發明之疫苗亦可與其他抗原混合成液體狀。 本發明更進—步提供第一次將如此疫苗應用於醫藥上。 本發明更進一步之具體實例提供可預防或改善Β型感冒 嗜血桿菌感染之方法,此方法包含投予無毒而有效量之本 發明疫苗。 -7- 本紙張尺度適用中國國家梯準(CNS ) Λ4規格(210X297公浼〉 ---------1------、-ST------線 f請先閲讀背面之注意事項再填寫本頁) Λ: B' 4 6*7 74 6 , 第δ51 〇7646號專利申請案 中文説明書修正頁(S7年9月) 五、發明説明( 下列實例説明本發明。 實例1 疫苗配方,其包含H1B多醣共軛於破傷風類毒素而吸附於 靖酸链。 B型感冒嗜血桿菌莢膜多醣(PRP)與破傷風類毒素(丁丁)共軛 物之合成 1 . a溴化氣偶聯 共價結合PRP和TT之進行係採用在NlH(chu c et al (1983)發展出之偶聯化學,對B型感冒嗜血桿菌與6八型肺炎 球菌之多醣與蛋白質共軛物之免疫生產力之進一步研究, Infec. Immunity, 245-25 6) = PRP之活化以溴化氰來控制狀況 ,而以己二酸醯肼當間隔基衍生之s 經衍生後’活化之多醣(PRP_AH)藉透析(dlafiltrati〇na 純化=偶聯二種已純化之成份(PRP_AH及ττ)是受碳二醯亞 胺聚合作用影響。共軛物再經由超濾和凝膠過濾純化以去 除反應物和未共梃之PRP和TT。 PRP-TT共輕物之合成 1 . b C D A P 偶聯 30爱克天然Hib PRP溶入6毫升之2M氣化鈉中.。225微升 的CDAP( 1·氰基_4-二甲胺基吡錠四氟硼酸鹽)加入多醣溶液 (每毫升由ϊ〇〇毫克在乙腈中之原溶液)。90秒後加入450微 升之0.2M三乙胺。活化過程在pH 1〇.〇於冰上進行ί分鐘於 室溫1分鐘3 90毫克之破傷風類毒素(最初ps/蛋白比爲1/3)加入活化後 -8- 本紙張尺度適闱中國國家榇準(CNS ) Λ4規格(210χ 297公漤) -----------t------iy------pi. (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標隼局貝工消费合作社印裝 467746 經濟部中央標準局員工消費合作社印製 A7 ___B7 __五、發明説明(6 ) 之多醣偶聯反應於室溫進行1小時。之後以3毫升之pH 5 〇 ,1M甘胺酸溶液於室溫壓制(guenched)30分鐘再於4°C過夜 〇 共梃物以凝膠過滤純化用以0.2M氣化納平衡之sephacryl HR 500管柱來造行。每一分份均測其碳水化合物及蛋白質 含量。合併共辄物並以減菌過滤(膜Minisart㊉0.222rm)。 吸附於磷酸鋁 l.c將12.5 meg實例1(a)之多醣共軛物加入0.15毫克之磷酸 銘。將此携;拌兩小時,調整pH至5.1。此混合物靜置室溫一 天而吸附的共耗物再留置2-8°C 9天。在準備冷凍乾燥產品 時,吸附產畀以乳糖(15_75毫克)來稀釋,最終含每毫升25 微克多醣及0.4毫克鋁,將所得组合物裝入〇.5毫升小瓶中 冷凉·乾躁。 準備液態產品時,吸附之共軛物以水稀釋以供注射,加 150 mM氯化鈉及每毫升5毫克之苯氧基乙醇以達最終含量 每毫升20微克多醣及0.32毫克鋁。 l.d白喉破傷風及百日咳(無細胞)疫苗之配方加或不加b型 肝炎均依照"WO 93/24148(SmithKline Beecham Biologicals) 方法製備9 l.e 1低比例'PRP-TT磷酸鋁預先吸·附共軛物之製備a 共辄物的製備採與實例1 a相似之方法,但用較少量之破 傷風(30微克,60微克),得到多醣:蛋白質比爲1 : 1或i : 2之產物。此共軏物照實例1 c.方法吸附於磷酸銘。最終冷 凍乾燥之製備物含1λ5微克共軛物,0.15毫克磷酸鋁,15.75 .(請先聞讀背面之注意事項再填寫本頁) -9- 本紙張Λ度適用中國國家標準{ CNS ) A4規格(210X29^釐) /! 6 7 74 6 A7 B7 五、發明説明(7 ) 毫克乳糖。此劑於注射前以0.5毫升水重組於pH 0.1 土 0.1。 實例2 : PRP-TT共軛物預先吸附於磷酸鋁並與DTPa或DTPa- 1 -- ----' HB混合之免疫生產力 實例1 a)之Hib共耗物,原狀或預—朱吸附於鱗酸銘(兩種疫 苗均冷凍乾燥)與DTPa與DTPa-HB於注射1小時之前混合, 而此混合物以皮下注射於小鼠(1週齡)用相當於1/20之人類 劑量(〇, 5微克的PRP)。小鼠經二週及四週後再次注射,每 次注射完均採集其血清測量抗PRP之抗體。對照組包括Hib. 疫苗(吸附或未吸附於磷酸鋁)重組於生理食鹽水中。 各组含10隻逢機取樣小鼠(一週齡一OFA品系)於0-14-28 日以1/20人類劑量之Hib疫苗以皮下注射共三次,疫苗可能 是單獨或與DTPa或DTPa-HB混合的。經冷凍乾燥之Hib疫 苗與生理食鹽水重组或於注射一小時之前與DTPa或DTPa-HB混合。 小鼠在14-28-42及56天經麻醉抽血。抗PRP之抗體以 ELISA方法由各個體之血清中測量效價,用經校正之參考 以r/毫升表示。每組於各定時之GMT均計算出來。第三次 注射後,效價以95%可信度限制計算。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填笃本頁) 如表1所示,Hib共輥物吸附於鱗酸铭並未改變其免疫生 產力:有些抗-PS在第二劑後即產生了,且在第三劑後有顯 著的促進效果,正如在人類婴兒中所見一般。Hib疫苗與_ DTPa或DTPa-HB混合使抗-PRP良應降低3到8倚,在DTPa-HB情形,此降低是顯著的。相對地,里直將租空瘴苗吸股 於磷酸鋁恢復了抗-PRP反應至少回到相當於原疫苗的水平 -10- 本紙張尺度適用中國國家標準(CNTS ) Α4規格(2! 0 X 297公釐) 4 6 7 74多85107646號專利申請案 ^ 乃年州以 中文説明書修正頁(S7年9月) ^ --五、發明説明(8 ) 結論: H i b /磷酸鋁配方具有解決相容性問題的潛力,此類問題 常於H i b與其他小兒疫苗合用時遇到。 表1 以小鼠爲模式,PRP-TT共軛物預先吸附於磷酸鋁並與DTPa 或DTPa-HB混合之免疫生產力 疫苗 當曰抗-PRP效價(r/毫升) 14(第一次 28(第二;欠 42<;第三次 56(第三次 mm 蹄後) mm 湖獅日) 無(Nacl 0.9%) <0.05 <0.05 <0.05 <0.05 Hib-001 <0.05 0.06 12.9(4-37) IM(4-31) Hib/磷酸鋁(Dhib-〇24) <0.05 1.3 11.8^5-29^ 15,4(7-35) Hib-001+DTPa(119) <0.05 0.16 3.4(0-28) 1.4(0.1-17) Hib/磷酸鋁+DTPa(119) <0.05 1.9 20.9^7-59^ 19.7Γ9.42) Hib-00 l+DTPa-HB( 16705) <0.05 0.14 2.8(1-6) 3.9(2-9) Hib/鱗酸铭+DTPa-HB(l 6705) <0.05 0.47 11.4^5-27^ 18.1(9-38) Hib/氫氧化鋁 <0.05 <0.05 <0.05 <0.14 DTPa :白喉、百日咳及破傷風组合疫苗’且含B型肝炎病毒抗原 (請先閱讀背面之注意事項再填寫本頁) .¾ -sck 經濟部中央標隼局員工消资合作社印製 DTPaHB :白喉' 百日咳及破傷風組合疫苗,不含B型肝炎病毒抗原。 Hibool :説明書第10頁第8至9行之食鹽水中基本ΗΛ—共軛物配方 Dhib-024 :生產批號。 -11 - 本紙張尺度適用中國國家標準(CNS ) Λ4说格(2lOX2M公勢-)
Claims (1)
- 經濟部中央橾準局具工消費合作社印裝 6 7 6 弟85107646號專利申請案 Μ 中文申請專利範圍修正本(9〇年2月)品 六、申請專利範圍 1· 一種综合疫苗’其包括與載體蛋白質共軛之B型感冒嗜 血桿菌之莢膜多醣,以及至少一種其他抗原,特徵在 於該共概物係吸附於蹲酸鋁上。 2. —種综合疫苗,其包括與載體蛋白質共軛之b型感冒嗜 血桿菌之莢膜多醣’並與一種或多種選自以下群組之 抗原混合:A型肝炎病毒、白喉、破傷風、百曰咳、 B型肝炎病毒及小兒麻痒病毒;特徵在於該共軛物係 吸附於鱗酸銘上。 3. 根據申請專利範圍第丨或2項之综合疫苗,其包括與載體 蛋白質共軛之B型感冒嗜血捍菌之莢膜多醣;其中載體 蛋白質係選自白喉類毒素’白喉CRM197蛋白質,腦 膜炎球菌外膜蛋白質及破傷風類毒素β 4·根據申請專利範園第1或2項之综合疫苗,其中與b型感 W嗜血〜趕菌之莢膜多醣共軛之載體蛋白質為破傷風類毒 素。 5.根據申請專利範圍第1或2項之综合疫苗,其中b型感冒 哮血捍菌之莢膜多醣與載體蛋白之比例自1 : 〇 3至 1 : 2( W : W)。 6·根據申請專利範圍第1或2項之综合疫苗,其中被吸附之 共軏物為冷;東乾燥的。 7·根據申請專利範圍第1或2項之综合疫苗,其中被吸附之 共軛物係懸浮於水以供注射。 種生產報據申請專利範圍第1至6項中任一項之疫苗之 方法,其包括將多醣抗原共軛至蛋白質載體,並與一或 表紙張尺度適用中理國家揉率(CNS ) Α4· ( 21〇χ297公董) {請先閲讀背面之注意事項再填寫本頁) ..Λ - 467746 A8 B8 C8 ______ D8 六、申請專利範圍 多種選自下列群組之其他抗原混合:A型肝炎病毒、白 喉、破傷風、百曰咳、B型肝炎病毒及小兒麻痺病 毒;且將該等抗原吸附於磷酸鋁之上。 9·根據申請專利範圍第1或2項之综合疫苗,其係作為醫藥 品。 W.根據申請專利範圍第I或2項之综合疫苗,其係用於治療 +罹患或遭受B型嗜血捍菌感染之病人。 (請先聞讀背面之注ί項再填寫本頁) 訂 經濟部中央標车局貝工消费合作社印製 2 本紙張尺度遙用中a國家梯準(CNS > Α4規格(210Χ297公釐) 公告本 __ 申請曰期 85. 6. 25. 案 號 85107646 類 别 f)b、k 巧/i〆 ,一 ^1 uaf.... ---'·- 經濟部中央標準局舅工消資合作社印製(以上各櫊由本局填註) Μ專利説明書 中 文 含吸附於鱗酸鋁上之Β型感冒嗜血捍菌抗原共輊物之組合 ,發明ϋ 疫苗及其製法 / ㈣名% 英 文 'COMBINATION VACCINES COMPRISING ALUMINIUM PHOSPHATE ADSORBED ΗΓΒ CONJUGATES AND THE METHOD FOR THE J PRODUCTION THEREOF" 姓 名 1. 茱利恩皮特曼 2. 皮爾.郝瑟 __發明, 一、騰 國 籍 住、居所 1-2.均比利時 1-2.均比利時利克森沙特市第一學院路89號 姓 名 (名稱) 比利時商史密斯克菜美占生物公司 國 籍 ·_ 比利時 三,申請人 住、居所 (事務所) 比利時利克森沙特市第一學院路89號 代表人 ^ 名詹恩·史帝芬 本紙張尺度適用中國國家操準(CNS〉六4規格(2^x297公釐) 4 67 74 6 第85107646號專利申請案 中文説明書修正頁(87年9月) Λ' ir ^ η2- 經濟部中夬標準局員工消費合作社印製 五、發明説明(1 ) 本發明有關新穎疫苗配方,其包括連接於載體蛋白質之 共軛多醣抗原。本發明特別是有關於預防B型感冒嗜血桿 菌(Hib)感染之疫苗配方,且其抗原吸附在磷酸鋁上。本 發明亦有關於多價疫苗,此類疫苗可以同時改善或治療多 種疾病。本發明亦有關於此類疫苗之生產及其作爲藥物之 用途 應用多醣類作爲疫苗是已知的技藝。例如有預防B型感冒 嗜血桿菌(Hib)感染之疫苗是以與載體蛋白質共軛之被膜 多醣(PRP)爲基礎。此多醣爲由核糖,核糖醇及磷酸而成之 聚合物。這類疫苗通常是單純的配方(不含佐劑)。然而有 一種製劑 (Merck生產之Pedvax Hib)是用含有氫氧化銘之 稀釋液去重组經冷凍乾燥之共軛物。通常載體蛋白質是白 喉或破傷風類毒素或是腦膜炎奈瑟氏球菌(N. menigitidis) 之外膜蛋白質。如此類共軛疫苗抗原之例子揭示如US 4 365 170,US 4 673 574,EP 208 375,EP 477 508及 EP 161 188 ° 一般係欲將此類共軏疫苗與其他的抗原或疫苗同時投藥 ,這可能需作多次注射。多次注射的問題在於投藥的步驟 較複雜及較大的總注射量。當疫苗是用於婴兒時這種問題 更加嚴重。 因此一般均建議生產综合疫苗。其中最熟知的综合疫苗 可以同時抗白喉、破傷風和百日咳感染。此疫苗包含一完 整細胞或非細胞的百日咳成份,通常由2到3個抗原-(去毒 的PT,FHA且常爲但並非只爲69kDa),雖然在某些情況下 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公漦) (請先閱讀背面之注意事項再填寫本頁) 裝. 訂 β 經濟部中央標準局貝工消費合作社印繁 4 ! ί 好'' ^ 7- ^!·: ; w— —... .74 6 第85 1 〇7646號專利申請案 中文說明書修正頁(87年9月) 五、發明説明(4 ) Beecham BioI〇gicais(i991)出版]。B 型肝炎成份包括 ”s,,枋 原如 ’’Engerix-B"中者= 依本發明所製之B型感冒嗜血桿菌或综合疫苗之極有利 處是它們亦是小兒疫苗3 疫苗之製備揭示於疫苗設計·次單元與佐劑之取向,Ed Powell and Newman; Pellum Press 3 包入脂質體係如 Fullerton,美國專利4,235,877中所描述》蛋白質與大分子 之共梃係如Likhite美國專利4,372,945及Armor等人之美國專 利4,474, 757中所描述。 存在於各個疫苗中共扼抗原之量取決於該量可誘導免疫 保護反應而又無顯著的副作用=此量與用那一個特定的免 疫原有關。通常希望每一劑含1 · 1000微克的免疫原,較佳 是含2-100微克,最佳是含4-40微克。每一特定疫苗之最佳 量可藉標準研究來確定,包括觀察抗體效價及個體之其他 反應。經初次注射疫苗後,個體可能仍需在四個星期間隔 給予一或兩次的補助注射。 本發明更進一步提供一種生產疫苗之方法,包含將共軛 抗原吸附於磷酸鋁3吸附最好是在p Η 5至6間進行,較佳 爲約5,4。在具體實例中,疫苗經多於2 4小時之靜置後冷 凍乾燥。本發明之疫苗亦可與其他抗原混合成液體狀。 本發明更進—步提供第一次將如此疫苗應用於醫藥上。 本發明更進一步之具體實例提供可預防或改善Β型感冒 嗜血桿菌感染之方法,此方法包含投予無毒而有效量之本 發明疫苗。 -7- 本紙張尺度適用中國國家梯準(CNS ) Λ4規格(210X297公浼〉 ---------1------、-ST------線 f請先閲讀背面之注意事項再填寫本頁) Λ: B' 4 6*7 74 6 , 第δ51 〇7646號專利申請案 中文説明書修正頁(S7年9月) 五、發明説明( 下列實例説明本發明。 實例1 疫苗配方,其包含H1B多醣共軛於破傷風類毒素而吸附於 靖酸链。 B型感冒嗜血桿菌莢膜多醣(PRP)與破傷風類毒素(丁丁)共軛 物之合成 1 . a溴化氣偶聯 共價結合PRP和TT之進行係採用在NlH(chu c et al (1983)發展出之偶聯化學,對B型感冒嗜血桿菌與6八型肺炎 球菌之多醣與蛋白質共軛物之免疫生產力之進一步研究, Infec. Immunity, 245-25 6) = PRP之活化以溴化氰來控制狀況 ,而以己二酸醯肼當間隔基衍生之s 經衍生後’活化之多醣(PRP_AH)藉透析(dlafiltrati〇na 純化=偶聯二種已純化之成份(PRP_AH及ττ)是受碳二醯亞 胺聚合作用影響。共軛物再經由超濾和凝膠過濾純化以去 除反應物和未共梃之PRP和TT。 PRP-TT共輕物之合成 1 . b C D A P 偶聯 30爱克天然Hib PRP溶入6毫升之2M氣化鈉中.。225微升 的CDAP( 1·氰基_4-二甲胺基吡錠四氟硼酸鹽)加入多醣溶液 (每毫升由ϊ〇〇毫克在乙腈中之原溶液)。90秒後加入450微 升之0.2M三乙胺。活化過程在pH 1〇.〇於冰上進行ί分鐘於 室溫1分鐘3 90毫克之破傷風類毒素(最初ps/蛋白比爲1/3)加入活化後 -8- 本紙張尺度適闱中國國家榇準(CNS ) Λ4規格(210χ 297公漤) -----------t------iy------pi. (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標隼局貝工消费合作社印裝 467746 經濟部中央標準局員工消費合作社印製 A7 ___B7 __五、發明説明(6 ) 之多醣偶聯反應於室溫進行1小時。之後以3毫升之pH 5 〇 ,1M甘胺酸溶液於室溫壓制(guenched)30分鐘再於4°C過夜 〇 共梃物以凝膠過滤純化用以0.2M氣化納平衡之sephacryl HR 500管柱來造行。每一分份均測其碳水化合物及蛋白質 含量。合併共辄物並以減菌過滤(膜Minisart㊉0.222rm)。 吸附於磷酸鋁 l.c將12.5 meg實例1(a)之多醣共軛物加入0.15毫克之磷酸 銘。將此携;拌兩小時,調整pH至5.1。此混合物靜置室溫一 天而吸附的共耗物再留置2-8°C 9天。在準備冷凍乾燥產品 時,吸附產畀以乳糖(15_75毫克)來稀釋,最終含每毫升25 微克多醣及0.4毫克鋁,將所得组合物裝入〇.5毫升小瓶中 冷凉·乾躁。 準備液態產品時,吸附之共軛物以水稀釋以供注射,加 150 mM氯化鈉及每毫升5毫克之苯氧基乙醇以達最終含量 每毫升20微克多醣及0.32毫克鋁。 l.d白喉破傷風及百日咳(無細胞)疫苗之配方加或不加b型 肝炎均依照"WO 93/24148(SmithKline Beecham Biologicals) 方法製備9 l.e 1低比例'PRP-TT磷酸鋁預先吸·附共軛物之製備a 共辄物的製備採與實例1 a相似之方法,但用較少量之破 傷風(30微克,60微克),得到多醣:蛋白質比爲1 : 1或i : 2之產物。此共軏物照實例1 c.方法吸附於磷酸銘。最終冷 凍乾燥之製備物含1λ5微克共軛物,0.15毫克磷酸鋁,15.75 .(請先聞讀背面之注意事項再填寫本頁) -9- 本紙張Λ度適用中國國家標準{ CNS ) A4規格(210X29^釐) 4 6 7 74多85107646號專利申請案 ^ 乃年州以 中文説明書修正頁(S7年9月) ^ --五、發明説明(8 ) 結論: H i b /磷酸鋁配方具有解決相容性問題的潛力,此類問題 常於H i b與其他小兒疫苗合用時遇到。 表1 以小鼠爲模式,PRP-TT共軛物預先吸附於磷酸鋁並與DTPa 或DTPa-HB混合之免疫生產力 疫苗 當曰抗-PRP效價(r/毫升) 14(第一次 28(第二;欠 42<;第三次 56(第三次 mm 蹄後) mm 湖獅日) 無(Nacl 0.9%) <0.05 <0.05 <0.05 <0.05 Hib-001 <0.05 0.06 12.9(4-37) IM(4-31) Hib/磷酸鋁(Dhib-〇24) <0.05 1.3 11.8^5-29^ 15,4(7-35) Hib-001+DTPa(119) <0.05 0.16 3.4(0-28) 1.4(0.1-17) Hib/磷酸鋁+DTPa(119) <0.05 1.9 20.9^7-59^ 19.7Γ9.42) Hib-00 l+DTPa-HB( 16705) <0.05 0.14 2.8(1-6) 3.9(2-9) Hib/鱗酸铭+DTPa-HB(l 6705) <0.05 0.47 11.4^5-27^ 18.1(9-38) Hib/氫氧化鋁 <0.05 <0.05 <0.05 <0.14 DTPa :白喉、百日咳及破傷風组合疫苗’且含B型肝炎病毒抗原 (請先閱讀背面之注意事項再填寫本頁) .¾ -sck 經濟部中央標隼局員工消资合作社印製 DTPaHB :白喉' 百日咳及破傷風組合疫苗,不含B型肝炎病毒抗原。 Hibool :説明書第10頁第8至9行之食鹽水中基本ΗΛ—共軛物配方 Dhib-024 :生產批號。 -11 - 本紙張尺度適用中國國家標準(CNS ) Λ4说格(2lOX2M公勢-) 74 6 第85 107646號專利申請案 中文説明書修正頁(87年9月) A5 B5 四、中文發明摘要(發明之名稱: 含吸附於磷酸鋁上之B型感冒嗜血桿菌抗原共 軛物之组合疫苗及其製法 本發明有關疫苗配方,其可用於預防B型感冒嗜血桿菌 (H i b )之感染且其抗原是吸附於磷酸鋁上。本發明亦有關 於多價疫苗,此類疫苗可以同時改善或治療多種疾病。本 發明亦有關於此類疫苗之生產及其作爲藥物之用途。 .. 英文發明摘要(發明之^稱: ''COMBINATION VACCINES COMPRISING ALUMINIUM PHOSPHATE ADSORBED HIB CONJUGATES AND THE METHOD FOR THE PRODUCTION THEREOF" 經濟部中央標準局員工消費合作社印製 The invention relates to a vaccine formulation for the prevention of Haemophilus Influenzae Type B (Hib) infections and where the antigen is adsorbed on to aluminium phosphate. The invention also relates to a multivalent vaccine, that is a vaccine for the amelionition or treatment of more than one disease states. The present invention also relates to the production and use of such vaccines in medicine. -2- 本紙張尺度適用中國國家標辛(CMS ) A4規格(210X297公釐) ----,-------SUM--裝----.--^訂----線 .-: (請先閱讀背面之注意事項再填寫本頁各櫊) 經濟部中央橾準局具工消費合作社印裝 6 7 6 弟85107646號專利申請案 Μ 中文申請專利範圍修正本(9〇年2月)品 六、申請專利範圍 1· 一種综合疫苗’其包括與載體蛋白質共軛之B型感冒嗜 血桿菌之莢膜多醣,以及至少一種其他抗原,特徵在 於該共概物係吸附於蹲酸鋁上。 2. —種综合疫苗,其包括與載體蛋白質共軛之b型感冒嗜 血桿菌之莢膜多醣’並與一種或多種選自以下群組之 抗原混合:A型肝炎病毒、白喉、破傷風、百曰咳、 B型肝炎病毒及小兒麻痒病毒;特徵在於該共軛物係 吸附於鱗酸銘上。 3. 根據申請專利範圍第丨或2項之综合疫苗,其包括與載體 蛋白質共軛之B型感冒嗜血捍菌之莢膜多醣;其中載體 蛋白質係選自白喉類毒素’白喉CRM197蛋白質,腦 膜炎球菌外膜蛋白質及破傷風類毒素β 4·根據申請專利範園第1或2項之综合疫苗,其中與b型感 W嗜血〜趕菌之莢膜多醣共軛之載體蛋白質為破傷風類毒 素。 5.根據申請專利範圍第1或2項之综合疫苗,其中b型感冒 哮血捍菌之莢膜多醣與載體蛋白之比例自1 : 〇 3至 1 : 2( W : W)。 6·根據申請專利範圍第1或2項之综合疫苗,其中被吸附之 共軏物為冷;東乾燥的。 7·根據申請專利範圍第1或2項之综合疫苗,其中被吸附之 共軛物係懸浮於水以供注射。 種生產報據申請專利範圍第1至6項中任一項之疫苗之 方法,其包括將多醣抗原共軛至蛋白質載體,並與一或 表紙張尺度適用中理國家揉率(CNS ) Α4· ( 21〇χ297公董) {請先閲讀背面之注意事項再填寫本頁) ..Λ -
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9512827.8A GB9512827D0 (en) | 1995-06-23 | 1995-06-23 | Vaccines |
GBGB9513443.3A GB9513443D0 (en) | 1995-07-01 | 1995-07-01 | Vaccines |
GBGB9525657.4A GB9525657D0 (en) | 1995-12-15 | 1995-12-15 | Vaccines |
GBGB9606032.2A GB9606032D0 (en) | 1996-03-22 | 1996-03-22 | Vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
TW467746B true TW467746B (en) | 2001-12-11 |
Family
ID=27451299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085107646A TW467746B (en) | 1995-06-23 | 1996-06-25 | Combination vaccines comprising aluminium phosphate adsorbed HIB conjugates and the method for the production thereof |
Country Status (36)
Country | Link |
---|---|
EP (2) | EP0833662B2 (zh) |
JP (2) | JP4850987B2 (zh) |
KR (1) | KR100425929B1 (zh) |
CN (1) | CN1146444C (zh) |
AP (1) | AP812A (zh) |
AR (1) | AR003006A1 (zh) |
AT (2) | ATE199831T1 (zh) |
AU (1) | AU696338B2 (zh) |
BG (1) | BG62720B1 (zh) |
BR (1) | BRPI9609414B8 (zh) |
CA (1) | CA2222455C (zh) |
CY (1) | CY2297B1 (zh) |
CZ (1) | CZ288908B6 (zh) |
DE (2) | DE69637950D1 (zh) |
DK (2) | DK1082965T3 (zh) |
DZ (1) | DZ2055A1 (zh) |
EA (1) | EA199700413A1 (zh) |
EG (1) | EG25924A (zh) |
ES (2) | ES2325301T3 (zh) |
GR (1) | GR3036088T3 (zh) |
HK (2) | HK1037516A1 (zh) |
HU (1) | HU224514B1 (zh) |
IL (1) | IL122588A (zh) |
MA (1) | MA23918A1 (zh) |
MY (1) | MY114786A (zh) |
NO (1) | NO325169B1 (zh) |
NZ (1) | NZ312132A (zh) |
OA (1) | OA10646A (zh) |
PE (1) | PE11298A1 (zh) |
PL (1) | PL184872B1 (zh) |
PT (2) | PT833662E (zh) |
SI (2) | SI1082965T1 (zh) |
SK (1) | SK176197A3 (zh) |
TR (1) | TR199701682T1 (zh) |
TW (1) | TW467746B (zh) |
WO (1) | WO1997000697A1 (zh) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0835663T3 (da) | 1992-05-23 | 2010-02-01 | Glaxosmithkline Biolog Sa | Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener |
US6468765B1 (en) | 1995-04-21 | 2002-10-22 | Human Genome Sciences, Inc. | Selected Haemophilus influenzae Rd polynucleotides and polypeptides |
US6355450B1 (en) | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
US6696065B1 (en) | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
ES2325301T3 (es) * | 1995-06-23 | 2009-09-01 | Glaxosmithkline Biologicals S.A. | Composicion de vacuna que comprende un antigeno polisacarido conjugado, adsorbido sobre fosfato de aluminio. |
SK283565B6 (sk) * | 1996-07-02 | 2003-09-11 | Connaught Laboratories Limited | Multivalentná imunogénna kompozícia a jej použitie |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
ATE357252T1 (de) | 1998-10-16 | 2007-04-15 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
US6585973B1 (en) | 1998-10-29 | 2003-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for preparing solid phase conjugated vaccine |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
PE20020126A1 (es) | 2000-06-29 | 2002-04-27 | Smithkline Beecham Biolog | Composicion de vacuna |
CA2435681C (en) | 2001-01-23 | 2011-06-21 | Aventis Pasteur | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
ES2608048T3 (es) | 2002-10-11 | 2017-04-05 | Glaxosmithkline Biologicals Sa | Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos |
DK2395073T3 (en) | 2002-11-01 | 2017-10-23 | Glaxosmithkline Biologicals Sa | Process for drying. |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CA2514328C (en) | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
DK1961426T3 (da) | 2003-10-02 | 2011-08-08 | Novartis Ag | Kombinationsvacciner mod meningitis |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
ES2346314T3 (es) * | 2003-10-02 | 2010-10-14 | Glaxosmithkline Biolog Sa | Antigenos de b. pertussis y uso de los mismos en vacunacion. |
GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
RU2379052C2 (ru) | 2004-04-30 | 2010-01-20 | Чирон С.Р.Л. | Вакцинация менингококковыми конъюгатами |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
BRPI0610297A2 (pt) | 2005-04-18 | 2010-06-08 | Novartis Vaccines & Diagnostic | expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina |
CA2611960C (en) | 2005-06-27 | 2015-05-05 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions comprising n.meningitidis capsular saccharide conjugates |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TR201807355T4 (tr) | 2006-03-22 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Meningokokkal konjugatlarla immünizasyon rejimleri. |
US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
ES2387582T3 (es) | 2006-09-07 | 2012-09-26 | Glaxosmithkline Biologicals S.A. | Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio |
CA2685506A1 (en) | 2007-05-02 | 2008-11-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
MX2009013112A (es) | 2007-06-04 | 2010-03-01 | Novartis Ag | Formulacion de vacunas para meningitis. |
FR2918671B1 (fr) * | 2007-07-10 | 2010-10-15 | Sanofi Pasteur | Milieu de culture d'haemophilus influenzae type b. |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
TW201043267A (en) * | 2009-03-19 | 2010-12-16 | Intervet Int Bv | In situ constituting a vaccine for administration to a predetermined herd of animals |
AU2010227219B2 (en) * | 2009-03-24 | 2014-02-27 | Glaxosmithkline Biologicals S.A. | Adjuvanting meningococcal factor H binding protein |
IT1398927B1 (it) | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
CN103442730B (zh) | 2011-01-05 | 2016-08-17 | 巴拉特生物技术国际有限公司 | 组合七价疫苗 |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
DE102011118371B4 (de) | 2011-11-11 | 2014-02-13 | Novartis Ag | Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
DE102011122891B4 (de) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen |
EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
WO2013113729A1 (en) | 2012-02-01 | 2013-08-08 | Glaxosmithkline Biologicals S.A. | Fermentation process |
WO2014009971A2 (en) * | 2012-07-07 | 2014-01-16 | Bharat Biotech International Limited | Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP2015525794A (ja) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法 |
US20150273036A1 (en) | 2012-10-12 | 2015-10-01 | Glaxosmithkline Biologicals Sa | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
EP3492097A1 (en) | 2013-08-05 | 2019-06-05 | GlaxoSmithKline Biologicals S.A. | Combination immunogenic compositions |
US11219680B2 (en) | 2017-02-24 | 2022-01-11 | Merck Sharp & Dohme Corp. | Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier |
GEP20227386B (en) | 2017-07-18 | 2022-06-10 | Serum Institute Of India Pvt Ltd | Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
JOP20190242A1 (ar) | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
CA3141460A1 (en) | 2019-05-20 | 2020-11-26 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
CN111658617A (zh) * | 2019-10-14 | 2020-09-15 | 四川大学 | 一种含铝佐剂疫苗的冻干制剂及其制备方法和用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
DE69113564T2 (de) * | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
NZ249704A (en) | 1992-02-11 | 1996-11-26 | Jackson H M Found Military Med | A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct |
DK0835663T3 (da) | 1992-05-23 | 2010-02-01 | Glaxosmithkline Biolog Sa | Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener |
SG47725A1 (en) * | 1992-10-27 | 1998-04-17 | American Cyanamid Co | Combination pediatric vaccine with enhanced immunogenicity of each vaccine component |
ES2325301T3 (es) * | 1995-06-23 | 2009-09-01 | Glaxosmithkline Biologicals S.A. | Composicion de vacuna que comprende un antigeno polisacarido conjugado, adsorbido sobre fosfato de aluminio. |
-
1996
- 1996-06-19 ES ES00203874T patent/ES2325301T3/es not_active Expired - Lifetime
- 1996-06-19 DK DK00203874T patent/DK1082965T3/da active
- 1996-06-19 AP APAP/P/1997/001159A patent/AP812A/en active
- 1996-06-19 CA CA2222455A patent/CA2222455C/en not_active Expired - Lifetime
- 1996-06-19 CN CNB961949732A patent/CN1146444C/zh not_active Expired - Lifetime
- 1996-06-19 TR TR97/01682T patent/TR199701682T1/xx unknown
- 1996-06-19 IL IL12258896A patent/IL122588A/en not_active IP Right Cessation
- 1996-06-19 AT AT96922871T patent/ATE199831T1/de active
- 1996-06-19 EP EP96922871A patent/EP0833662B2/en not_active Expired - Lifetime
- 1996-06-19 EA EA199700413A patent/EA199700413A1/ru unknown
- 1996-06-19 SI SI9630768T patent/SI1082965T1/sl unknown
- 1996-06-19 CZ CZ19974189A patent/CZ288908B6/cs not_active IP Right Cessation
- 1996-06-19 DE DE69637950T patent/DE69637950D1/de not_active Expired - Lifetime
- 1996-06-19 BR BRPI9609414A patent/BRPI9609414B8/pt not_active IP Right Cessation
- 1996-06-19 AT AT00203874T patent/ATE433329T1/de active
- 1996-06-19 AU AU63591/96A patent/AU696338B2/en not_active Expired
- 1996-06-19 KR KR1019970709651A patent/KR100425929B1/ko not_active IP Right Cessation
- 1996-06-19 JP JP50358197A patent/JP4850987B2/ja not_active Expired - Lifetime
- 1996-06-19 ES ES96922871T patent/ES2157447T5/es not_active Expired - Lifetime
- 1996-06-19 SI SI9630310T patent/SI0833662T2/sl unknown
- 1996-06-19 DK DK96922871.7T patent/DK0833662T4/da active
- 1996-06-19 WO PCT/EP1996/002690 patent/WO1997000697A1/en active IP Right Grant
- 1996-06-19 EP EP00203874A patent/EP1082965B1/en not_active Expired - Lifetime
- 1996-06-19 PL PL96324242A patent/PL184872B1/pl unknown
- 1996-06-19 PT PT96922871T patent/PT833662E/pt unknown
- 1996-06-19 NZ NZ312132A patent/NZ312132A/en not_active IP Right Cessation
- 1996-06-19 DE DE69612198T patent/DE69612198T3/de not_active Expired - Lifetime
- 1996-06-19 HU HU9900061A patent/HU224514B1/hu active IP Right Grant
- 1996-06-19 SK SK1761-97A patent/SK176197A3/sk unknown
- 1996-06-19 PT PT00203874T patent/PT1082965E/pt unknown
- 1996-06-21 MY MYPI96002531A patent/MY114786A/en unknown
- 1996-06-21 MA MA24292A patent/MA23918A1/fr unknown
- 1996-06-21 PE PE1996000474A patent/PE11298A1/es not_active IP Right Cessation
- 1996-06-21 AR ARP960103253A patent/AR003006A1/es active IP Right Grant
- 1996-06-22 DZ DZ960099A patent/DZ2055A1/fr active
- 1996-06-22 EG EG57496A patent/EG25924A/xx active
- 1996-06-25 TW TW085107646A patent/TW467746B/zh not_active IP Right Cessation
-
1997
- 1997-12-19 OA OA70169A patent/OA10646A/en unknown
- 1997-12-22 NO NO19976035A patent/NO325169B1/no not_active IP Right Cessation
- 1997-12-23 BG BG102146A patent/BG62720B1/bg unknown
-
1998
- 1998-09-23 HK HK01106309.2A patent/HK1037516A1/xx not_active IP Right Cessation
- 1998-09-23 HK HK98110884A patent/HK1009764A1/xx not_active IP Right Cessation
-
2001
- 2001-06-19 GR GR20010400933T patent/GR3036088T3/el unknown
-
2002
- 2002-09-23 CY CY0200056A patent/CY2297B1/xx unknown
-
2008
- 2008-02-14 JP JP2008033301A patent/JP2008120833A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW467746B (en) | Combination vaccines comprising aluminium phosphate adsorbed HIB conjugates and the method for the production thereof | |
CA2221511C (en) | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein | |
US20070116714A1 (en) | Vaccine Comprising a Polysaccharide Antigen-Carrier Protein Conjugate and Free Carrier Protein | |
ES2224252T3 (es) | Composicion de vacuna que comprende fragmentos de la proteina de membrana externa de bordetella pertussis. | |
MXPA97010521A (en) | A composition of vaccines including an antigen conjugated of polysaccharid adsorbided in alumi phosphate | |
SA96170157B1 (ar) | تركيب لقاح composition vaccine يشتمل على مولد مضاد متعدد سكريد مقترن antigen conjugated polsaccharide يتم امتزازه على فوسفات الألومنيوم aluminum phosphate | |
MXPA97009732A (en) | Vaccine comprising a conjugate of antigen depolisacarido protein carrier and protein carrier li |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |